Franco Valle
Directeur Financier/CFO chez BIOMEA FUSION, INC.
Fortune : 267 435 $ au 30/04/2024
Postes actifs de Franco Valle
Sociétés | Poste | Début | Fin |
---|---|---|---|
BIOMEA FUSION, INC. | Comptroller/Controller/Auditor | 26/07/2021 | - |
Directeur Financier/CFO | 26/07/2021 | - |
Historique de carrière de Franco Valle
Anciens postes connus de Franco Valle
Sociétés | Poste | Début | Fin |
---|---|---|---|
EIDOS THERAPEUTICS, INC. | Comptroller/Controller/Auditor | 01/01/2020 | 01/04/2021 |
Directeur Financier/CFO | 01/01/2020 | 01/04/2021 | |
Corporate Officer/Principal | 01/03/2018 | 01/01/2020 | |
IOVANCE BIOTHERAPEUTICS, INC. | Comptroller/Controller/Auditor | 01/07/2016 | 01/01/2018 |
Directeur Financier/CFO | 26/07/2017 | 14/08/2017 | |
Pharmacyclics, Inc.
Pharmacyclics, Inc. Pharmaceuticals: MajorHealth Technology Pharmacyclics, Inc. develops drugs to treat cancer. The private company is based in Sunnyvale, CA. Robert William Duggan has been the CEO of the company since 2015. | Comptroller/Controller/Auditor | 01/01/2012 | 01/05/2015 |
PHARMACYCLICS, INC. | Comptroller/Controller/Auditor | - | - |
LENZ THERAPEUTICS, INC. | Directeur Financier/CFO | - | - |
Formation de Franco Valle
San Jose State University | Undergraduate Degree |
Statistiques
Internationale
Etats-Unis | 7 |
2 |
Opérationnelle
Comptroller/Controller/Auditor | 5 |
Director of Finance/CFO | 4 |
Undergraduate Degree | 1 |
Sectorielle
Health Technology | 6 |
Consumer Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 1 |
---|---|
IOVANCE BIOTHERAPEUTICS, INC. | Health Technology |
Entreprise privées | 5 |
---|---|
Pharmacyclics LLC
Pharmacyclics LLC Pharmaceuticals: MajorHealth Technology Pharmacyclics LLC engages in developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. It has product candidates in clinical development and several preclinical molecules in optimization. The company was founded by Jonathan Sessler and Richard Miller in 1991 and is headquartered in Sunnyvale, CA. | Health Technology |
Eidos Therapeutics, Inc.
Eidos Therapeutics, Inc. BiotechnologyHealth Technology Eidos Therapeutics, Inc. focuses on addressing the large and growing unmet need in diseases caused by transthyretin (TTR) amyloidosis (ATTR). Its product include the AG10, an orally-administered small molecule designed to potently stabilize TTR, suggesting a treatment with the potential to halt the progression of ATTR. The company was founded by Graef Isabella and Alhamadsheh Mamoun on August 6, 2013 and is headquartered in San Francisco, CA. | Health Technology |
Graphite Bio, Inc.
Graphite Bio, Inc. BiotechnologyHealth Technology Graphite Bio, Inc. is a clinical-stage gene editing company. It engages in the business of developing therapies that harness targeted gene integration to treat or cure serious diseases. The company was founded by Matthew Porteus and Maria Grazia Roncarolo on June 1, 2017 and is headquartered in South San Francisco, CA. | Health Technology |
Biomea Fusion, Inc. | |
Pharmacyclics, Inc.
Pharmacyclics, Inc. Pharmaceuticals: MajorHealth Technology Pharmacyclics, Inc. develops drugs to treat cancer. The private company is based in Sunnyvale, CA. Robert William Duggan has been the CEO of the company since 2015. | Health Technology |
- Bourse
- Insiders
- Franco Valle
- Expérience